Navigation Links
Penn study finds direct role for glial cells in brain cross-talk

Findings may help elucidate mechanisms of wake-sleep transitions and epileptic seizures

Researchers at the University of Pennsylvania School of Medicine have demonstrated that star-shaped glial cells in the brain called astrocytes are directly involved in regulating communication between neurons. A central finding of the study is that astrocytes modulate the level of a signaling molecule called adenosine, which is thought to be important in controlling wake-to-sleep transitions and epileptic seizures.

"This finding may cause neuroscientists to radically alter their view of the role of astrocytes as merely supportive to one of actively communicating with and instructing neurons," states senior author Philip G. Haydon, PhD, Professor of Neuroscience. "Astrocytes are not just the 'kitchen cells' of the brain, providing nutritional support, but instead also help the neurons talk to each other." Haydon and colleagues published their results in last week's issue of Science.

The central nervous system, which includes the brain and spinal cord, is composed of specialized cells called neurons that send out and receive chemical signals called neurotransmitters across a space called the synapse. This process results in transmission of a nerve impulse. Historically, the glial cell or astrocyte was considered to be a support cell and to play no active role in regulating nerve impulse transmission. However, recent research by Haydon and other investigators has indicated that glial cells do produce chemical transmitters called gliotransmitters and that these chemical signals are recognized by the neurons. The studies that have shown capability were conducted on isolated nerve cells or on slices of brain tissue.

In this most recent study, the researchers made genetic manipulations to glial cells in live mice, thus directly demonstrating how astrocytes function in the brain. The mice were engineered to produce a protein called SNARE in their astrocyt
'"/>

Source:University of Pennsylvania School of Medicine


Page: 1 2

Related biology news :

1. Bioartificial kidney under study at MCG
2. W.M. Keck Foundation funds study of friendly microbes
3. Yellowstone microbes fueled by hydrogen, according to U. of Colorado study
4. Genome-wide mouse study yields link to human leukemia
5. Clam embryo study shows pollutant mixture adversely affects nerve cell development
6. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
7. Same mutation aided evolution in many fish species, Stanford study finds
8. Sequencing of marine bacterium will help study of cell communication
9. Genetically modified rice in China benefits farmers health, study finds
10. A new study examines how shared pathogens affect host populations
11. NYU study reveals how brains immune system fights viral encephalitis
Post Your Comments:
Breaking Biology Technology:BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement 2BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 2BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 3BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 2Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 5